Difference between revisions of "Novartis"

From SourceWatch
Jump to navigation Jump to search
(SW: →‎Company History: add full refs, cull kess useful material)
(centered Novartis logo)
 
(36 intermediate revisions by 8 users not shown)
Line 1: Line 1:
−
{{GlobalCorpWiki}}
 
−
 
 
{{Infobox Company
 
{{Infobox Company
 
| company_name = Novartis
 
| company_name = Novartis
−
| company_logo = [[Image:novartis_logo.gif|thumb|Novartis Logo]]
+
| company_logo = [[Image:novartis_logo.gif|thumb|center|Novartis Logo]]
 
| company_type = Private pharmaceutical company
 
| company_type = Private pharmaceutical company
 
| genre = Pharmaceutical drug producer and biotechnological researcher
 
| genre = Pharmaceutical drug producer and biotechnological researcher
Line 10: Line 8:
 
| dissolved =
 
| dissolved =
 
| location = Basel, Switzerland
 
| location = Basel, Switzerland
−
| locations =
 
−
| area_served =
 
−
| key_people =
 
−
| industry =
 
−
| products =
 
−
| services =
 
−
| revenue =
 
−
| operating_income =
 
−
| company_slogan =
 
−
| net_income =
 
−
| assets =
 
−
| num_employees = 67,653
 
−
| parent =
 
−
| equity =
 
−
| owner =
 
−
| divisions =
 
−
| subsid =
 
−
| homepage =
 
−
| footnotes =
 
 
}}
 
}}
 +
'''Novartis''' is a global [[pharmaceutical]] and [[biotechnology]] corporation with headquarters in Basel, Switzerland.  The company specializes in  biotechnological drugs, vaccines, over-the-counter pharmaceuticals, animal health care products, contact lenses and lense care products. It is the world's 5th largest vaccine producer.  It distributes in over 140 countries through approximately 100,000 associates. <ref>[http://www.novartis.com/about-novartis/people/index.shtml Welcome to Novartis], Novartis, January 2010</ref> Novartis and [[AstraZeneca]] spun-off and merged to become [[Syngenta]], a Swiss global agribusiness company formed in 2000 from the agrochemical and seed divisions of Novartis, and the agrochemicals and biotechnology research divisions of AstraZeneca.  Syngenta is the world’s second biggest player in agrochemicals and the third biggest seed producer. <ref>[http://www.corporatewatch.org.uk/?lid=212 Syngenta: A Corporate Profile], Corporate Watch, November 2002</ref>
 +
 
 +
In the fiscal year ending in December of 2009, the company reported sales of approximately $45.1 billion dollars and had 99,834 employees. <ref>[http://www.hoovers.com/company/Novartis_AG/htscri-1-1njea5.html Key Novartis AG Financials], Hoovers, accessed January 2011</ref>
  
−
'''Novartis''' is a pharmaceutical multinational from Switzerland that specializes in biotechnological drug production and distribution, as well as a vast array of consumer healthcare products, including the manufacturing of vaccines, the development of over-the-counter pharmaceuticals not requiring prescrptions, as well as animal healthcare products and the production of contact lenses and various lense care products. It is the world's 5th largest vaccine producer, and its presence is noted in over 140 countries worldwide through 100.000 or so associates<ref>[http://www.novartis.com/about-novartis/people/index.shtml "About Novartis: Facts"]</ref>. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to [[Nestlé]] on September, 2007.<ref>Novartis, [http://www.novartis.com/newsroom/media-releases/en/2007/1150584.shtml "Novartis completes divestment program with transfer of Gerber baby foods business"], Media Release, September 03, 2007.</ref>
+
Access Novartis's corporate rap sheet compiled and written by ''Good Jobs First'' [http://www.corp-research.org/novartis here].
  
−
==Company History==
+
__TOC__
  
−
Novartis was founded in 1996 as a result of the merger of Ciba-Geigy and Sandoz, both Swiss companies with a long history of pharmaceutical experience.<ref>Novartis, [http://www.novartis.com/about-novartis/company-history/index.shtml "Novartis History"], Novartis website, accessed December 2008.</ref> Following the merger, Novartis reorganized its activities, and spun out its chemicals activities as Ciba Specialty Chemicals, which, in January 1997, became an independent company.<ref>Ciba, [http://cibasc.com/index/cmp-index/cmp-about.htm "About Us"], Ciba website, accessed December 2008.</ref> {In September 2008 BASF bought Ciba).<ref>[http://www.corporate.basf.com/en/presse/mitteilungen/pm.htm?pmid=3229&id=V00-qN3bGDLaUbcp*WJ "BASF makes offer to acquire Ciba"], Media Release, September 15, 2008.</ref><ref>[http://www.iht.com/articles/2008/09/15/business/basf.php "BASF buys Swiss specialty chemicals maker Ciba"], ''International Herald Tribune'', September 15, 2008.</ref>
+
==Overview==
 +
[[Image:2007-associates.jpg|thumb|NOVARTIS ASSOCIATES BY REGION AND BUSINESS]]
  
−
Novartis combined its agricultural division with that of [[AstraZeneca]] to create [[Syngenta]] in November 2000.<ref>Syngenta, [http://www.syngenta.com/en/about_syngenta/companyhistory.html "Company History"], Syngenta website, accessed December 2008.</ref>
+
Novartis' four divisions are pharmaceuticals, vaccines and diagnostics; generics and consumer health. Its largest division is pharmaceuticals. Vaccine and Diagnostics manufactures vaccines and blood-screening tools.  Its Sandoz generics subsidiary produces generic drugs and active pharmaceutical ingredients.  The consumer health unit includes the brand names Benefiber, Excedrin and Theraflu.  It also includes contact lenses, eye care products, companion animal and agricultural animal products. See also Novartis products. <ref>[http://www.novartis.com/products/index.shtml Welcome to Novartis], Novartis, accessed December 2009</ref>
  
−
In 2003, Novartis created a new company named Sandoz, a subsidiary that bundles its generic drug production, reusing the predecessor brand.<ref>Sandoz, [http://www.sandoz.it/site/it/l_azienda/News/Notizie/pool/Novartis_toSandoz.pdf "Return of a traditional name: Novartis Generics rebranded as Sandoz"], Media Release, May 20, 2003.</ref>
+
Novartis has six major product lines: pharmaceuticals; vaccines & diagnostics; Sandoz generic drugs, Over-the Counter (OTC) self medication; animal products and CIBA vision contact lenses and lens-care products.  The company markets over 50 key pharmaceutical products.  In 2008 Novartis launched 11 products in the U.S. and the [[European Union]] (EU). <ref>[http://www.novartis.com/products/pharmaceuticals-therapeutic-area.shtml Welcome to Novartis: Pharmaceuticals], accessed December 2009</ref> Novartis' Vaccines and Diagnostics Division in vaccine development and blood-testing equipment.  The company is the fifth largest vaccine manufacturer in the world and the second largest supplier of influenza vaccines in he U.S. <ref>[http://www.novartis.com/products/vaccines.shtml Novartis Vaccines and Diagnostics Division"], Novartis, accessed December 2008</ref>
  
−
On 20 April 2006, Novartis acquired the California-based Chiron Corporation. Chiron was formerly divided into three units: Chiron Vaccines and Chiron Blood Testing, which now combine to form Novartis Vaccines and Diagnostics, and Chiron BioPharmaceuticals, to be integrated into Novartis Pharmaceuticals.<ref>[http://www.allbusiness.com/company-activities-management/company-structures-ownership/5392342-1.html "Chiron Shareholders Approve Novartis Acquisition"], ''Media Release'', April 19 2006.</ref>
+
Sandoz is the generic branch of Novartis pharmaceuticals.  It manufactures low cost pharmaceuticals no longer protected by patents. Key products include drugs for central-nervous-system, gastrointestinal and cardiovascular disorders as well as antibiotics and hormone therapies. <ref>[http://www.novartis.com/products/sandoz.shtml About Sandoz: Novartis' generic pharmaceuticals division], Norvartis, accessed January 2009</ref> The company's over the counter (OTC) division develops, manufactures and markets non-prescription self medication. <ref>[http://www.novartis.com/products/over-counter.shtml "Novartis' Over-the-counter product line"], Novartis, accessed January 2009</ref> Novartis manufactures products for companion animals and "the health and productivity of farm animals."  Products include treatments for disease and parasite infestations. <ref>[http://www.novartis.com/products/animal-health.shtml Novartis Animal Health], Novartis, accessed January 2009</ref> CIBA VISION specializes in contact lenses and lens-care production in over 70 countries. <ref>[http://www.novartis.com/products/ciba-vision.shtml CIBA Vision], Novartis, accessed January 2009</ref>
  
−
==Financial Highlights==
+
==Ties to the American Legislative Exchange Council==
  
−
(In USD millions, unless indicated otherwise)
+
In August 2011, Novartis representative Don Stetcher was given the [[American Legislative Exchange Council]]'s (ALEC's) 2011 [[ALEC Award Winners|Private Sector Member of the Year Award]].<ref>American Legislative Exchange Council, "Solutions for the States," 38th Annual Meeting agenda, on file with CMD, August 3-6, 2011</ref>
  
−
===2007===
+
{{about_ALEC}}
 +
==Animal testing==
 +
{{#ev:youtube|ZJpGpAWrIYo|300|right|Demonstrations against Huntingdon Life Sciences clients Novartis & Merck. - Washington, DC January 2008}}
  
−
Total Group net sales: 39 800
+
Novartis does [[animal testing]].
  
−
Continuing operations
+
===Facility information, progress reports & USDA-APHIS reports===
 +
For links to copies of a facility's [[U.S. Department of Agriculture]] (USDA)-Animal Plant Health Inspection (APHIS) reports, other information and links, see also [http://www.all-creatures.org/saen/res-fr.html Stop Animal Experimentation NOW!: Facility Reports and Information].  This site contains listings for all 50 states, links to biomedical research facilities in that state and PDF copies of government documents where facilities must report their animal usage. (Search: Cambridge, Massachusetts; San Diego, California.)
  
−
- Net sales: 38 072
+
This facility performed animal experiments involving pain or distress but no analgesics, anesthetics or pain relievers were administered.  For copies of this facility's USDA-APHIS reports, other information and links, see also Facility Reports and Information: Novartis Animal Vaccines, Inc., Larchwood, IA. <ref>[http://www.all-creatures.org/saen/ia/res-fr-ia-nav.html Facility Reports and Information: Novartis Animal Vaccines, Inc., Larchwood, IA],Stop Animal Experimentation NOW!, accessed January 2011</ref>
  
−
- Operating income excluding
+
This facility performed animal experiments involving pain or distress but no analgesics, anesthetics or pain relievers were administered.  For copies of this facility's USDA-APHIS reports, other information and links, see also Facility Reports and Information: Novartis Pharmaceuticals Corporation, East Hanover, NJ<ref>[http://www.all-creatures.org/saen/nj/res-fr-nj-npc.html Facility Reports and Information: Novartis Pharmaceuticals Corporation, East Hanover, NJ], SAEN, accessed January 2011</ref>
−
environmental and restructuring charges: 7 815
 
  
−
- Return on net sales (%): 20.5
+
===USDA AWA reports===
 +
As of May 26, 2009, the USDA began posting all inspection reports for animal breeders, dealers, exhibitors, handlers, research facilities and animal carriers by state.  See also [http://www.aphis.usda.gov/animal_welfare/inspection_list.shtml USDA Animal Welfare Inspection Reports].
  
−
- Operating income: 6 781
+
=== Contract testing ===
 +
Novartis contract tests out to [[Huntingdon Life Sciences]] (HLS). <ref>[http://www.shac.net/HLS/exposed/inside_hls/Inside_customers.html Inside Customers], SHAC.net, accessed December 2009</ref> HLS is the 3rd largest contract research organization (CRO) in the world and the largest animal testing facility in all of Europe.  Firms hire CROs to conduct animal toxicity tests for agrochemicals, petrochemicals, household products, pharmaceutical drugs and toxins.  HLS has a long history of gross animal welfare violations. See also [[Huntingdon Life Sciences]].
  
−
- Net income: 6 540
+
Novartis contract tests out to [[Covance Laboratories]]. <ref>[http://novartiskills.com/Crimes.htm Novartis - A Chronicle of Crimes], Novartiskills.com, acessed January 2010</ref> Covance has a long history of gross animal welfare violations. See also [[Covance Laboratories]].
  
−
Net income – Discontinued operations 5 428 377
+
==Animal cruelty & welfare violations==
 +
{{Template:Violation_Tracker}}
 +
===Dairies of Despair: banned report released in UK===
 +
In April 2003, the largest ever set of data concerning animal experiments in the United Kingdom was released following a defeat earlier in the month for a 30 month injunction by Novartis and its former British subsidiary, Imutran.  The documents revealed primates being used in the search for solutions to the chronic global shortage of human transplant organs.  Baboons were transported from the African savannahs to die in steel cages the size of toilet cubicles.  According to the documents, a quarter of the primates died from "technical failures".  Researchers describe monkeys and baboons dying in fits of vomiting and diarrhea.  Other symptoms were violent spasms, bloody discharges, grinding teeth and uncontrollable, manic eye movements.  Animals retreated within themselves, lying still in their cages until they were put of their misery.  Baboon W201m died of a stroke after two days of suffering from limb spasms and paralysis.  Baboon W205m was "sacrificed" after 21 days.  A genetically modified pig's heart had been attached to the vital arteries within its neck.  Researchers noted the heart was swelling way beyond its natural size with a strange yellow fluid seeping from the organ.
  
−
Net income – Total Group 11 968 7 202
+
Other animals never even made it to the Novartis contract laboratory, [[Huntingdon Life Sciences]] (HLS), suffering painful deaths en route. Faxes from global wildlife dealers reveal at least 50 baboons being taken from the African plains for the experiments. In one shipment, the creatures spent 34 hours in cramped transport crates; 10 hours longer than approved by the Home Office (which did not take any action.)  In another shipment, three monkeys were found dead with blood oozing from their nostrils at a Paris airport.  They had not been able to turn and lie down naturally.  The 1,274 pages of documentation revealed a "litany of failings", including at least 520 errors and omissions. <ref>Mark Townsend [http://observer.guardian.co.uk/uk_news/story/0,6903,940033,00.html Exposed: secrets of the animal organ lab], The Observer, April 2003</ref>
  
−
Basic earnings per share:
+
===Xenotransplantation===
 +
The 150 page Diaries of Despair report based on the documentation, provides the public with an unprecedented and extensive insight into the reality of vivisection in Britain.  Never before has so much secret information about animal experiments entered the public domain.  The report was effectively banned for almost two and a half years by an injunction by Imutran and Novartis in late September of 2000.  The leaked documentation reveals horrific animal suffering, corrects misleading public presentation of research and exposes government deception.  The five part report provides background information on xenotransplantation (transplanting organs of one species into another); an overview of the leaked documents and the rationale behind transgenic pigs as a potential source of xenografts.  It describe the suffering of primates used in the research and the legal framework regulating animal testing.  The report documents baboons and cynomolgus monkeys, from (in the case of the baboons) capture in the wild, through transportation half way across the world and their deaths in experiments conducted at HLS.<ref>[http://www.xenodiaries.org/overview.htm Dairies of Despair: The Secret History of pig-to-primate organ transplants], Uncaged Campaigns, accessed January 2010</ref>
  
−
- Continuing operations: 2.81
+
See also ''Dairies of Despair: Further Reading''. <ref>[http://www.xenodiaries.org/links.htm Dairies of Despair: Further Reading], Uncaged Campaigns, accessed January 2010</ref>
  
−
- Total Group: 5.15
+
Organ transplants are transplants are prohibitively expensive and of limited value.  However, selling transgenic pig parts and other organs is very profitable.  Novartis and its subsidiaries have killed thousands of animals and spent millions of dollars attempting to develop animal organs for transplantation into humans.  Xenotransplantation experiments have a long history of human and animal costs.  They have proved to be one of the greatest medical disasters of all time, for both animals and recipients.  Approximately 6,000 people are on waiting lists for human organs, an organ shortage which could largely be solved through default consent to organ donation after death.  See also [[Humane Movement]], section 5.
  
−
R&D investments: 6 430
+
===Imunopigs===
 +
In spite of 100 years of failed research, the quest to turn animals into spare parts warehouses continues and has done nothing to slow Novartis' search for an ''immunopig''; (pigs genetically manipulated to carry human genes.)  However, failed research has shown that animals transplanted with human genes do not have suitable spare parts for humans, any more than non-genetically altered animals do.  Other species such as hamsters, rabbits and monkeys have also been subjected to failed horrific and pointless xenotransplantation.  The surgeries are so monumentally unsuccessful that animals usually begin to die within minutes.
  
−
- As % of net sales: 16.9
+
===Organ failure, rejection & dangers to human health===
 +
The transplanted organs do not function or are rejected almost instantaneously.  In one experiment, a pig's kidney was accidentally transplanted into the abdomen of a monkey.  The victims are then overdosed with anesthetics and their spleens were removed.  Monkeys and baboons who survive xenotransplanation die of organ rejection, organ failure and infections from drug toxicity and impaired immune systems.  Novartis has subjected monkeys to lethal infections, lethal blood clotting, bleeding complications, viral and protozoal infections, lymph cancer, severe nausea, severe stomach inflammation and diarrhea, dehydration, fatal pneumonia, persistent wound infections, breakdowns, brain trauma, heart attacks, pneumonia and anemia.  Primates are also given massive doses of immune-suppressing drugs which cause internal hemorrhaging.  In one experiment, a swab was left in a monkey's abdomen which in turn caused a lethal infection.  Such incidents occur on a regular basis.
  
−
Number of associates: 98 200
+
Some animal viruses are impossible to eradicate and can infect humans.  Current and historic examples [[mad cow disease]], HIV, [[avian flu]] and the 1918 influenza epidemic.  Scientists have expressed concern that recipients of pig organs may pass viruses into the general population. <ref>[http://www.stopanimaltests.com/f_ten_worst_ceo.asp PETA Names the 10 Worst CEOs for Animals in Laboratories], [[People for the Ethical Treatment of Animals]], accessed December 2009</ref>, <ref>[http://www.peta.org/mc/factsheet_display.asp?ID=82 Xenografts: Frankenstein Science], PETA Media Center, accessed January 2010</ref> 
  
−
'''2006'''
+
===Induced schizophrenia & epilepsy in rats & mice===
 +
In experiments in Basel, Switzerland, rats Rats between 4 and 8 days age are deprived of oxygen.  Some are exposed to reduced oxygen content. Some of them are killed on the 11th day of oxygen deprivation and their brains cut out and examined.  Others are exposed to noise and rattled in steel cages until they begin to show symptoms of schizophrenia. Finally, on their 120th day the rats are killed.
  
−
Total Group net sales: 37 020
+
In experiments in Germany on rats supplied by the Basel laboratory, electrodes are implanted into the stomachs and brains of mice.  ''Pilokarpin'' (a drug used to treat dry mouth associated with cancer radiotion treatment) is then injected to induce epilepsy.  Some of the mice die due to the treatment and others are again killed and their brains examined.  Surviving mice and subjected to a second injection of the drug Diazepam (Valium).  They live up to 28 days with the implanted electrodes before they are killed. <ref>Journal of Neural Transmission 2007: 114, 239-248</ref>
  
−
Continuing operations:
+
===Drilling open the heads of cats===
 +
In Germany experiments, the heads of cats are drilled open and a glass plate is applied.  Pictures are shown to the cat and the brain is filmed through the glass plate.  The cats are killed after 30 to 45 minutes.  Martin Rausch of Novartis Pharma AG, Basel, Switzerland, participated in these experiments. <ref>Neuro Report 2001: 12, 1693-1698</ref>, <ref>[http://novartiskills.com/Crimes.htm Novartis: A Chronicle of Crimes: Animal Torture], Novartiskills.com, accessed January 2010</ref>
  
−
- Net sales: 34 393
+
==Drug safety issues==
  
−
- Operating income excluding
+
Novartis has been plagued by a number of recent drug safety issues, including the delay of its diabetes drug Galvus and "evaluating" the launch of a generic version of its Lotrel blood pressure treatment.  Novartis withdrew the bowel drug Zelnorm from US shelves in March of 2007.
−
environmental and restructuring charges: 7 642
 
  
−
- Return on net sales(%): 22.2
+
===Prexige banned in Australia===
 +
In August of 2007, Australia banned Novartis' [[Prexige]], after the deaths of two patients.  According to Australia's Therapeutic Goods Administration (TGA), it received 8 reports of serious liver damage, including two deaths and two liver transplants linked to the COX-2 painkiller.
  
−
- Operating income: 7 642
+
In spite of these developments, there were no plans to pull the drug elsewhere, according to a company spokes person.  The company also planned to proceed with filing for marketing approval in the United States.  COX-2s have been under a cloud since [[Merck]] withdrew [[Vioxx]] in 2004 after studies showed that it increased the risk for heart attacks.  There have also been concerns over other non-steroidal, anti-inflammatory drugs.  Prexige had been viewed as a blockbuster seller for Novartis until the Vioxx withdrawal. <ref>[http://www.swissinfo.ch/eng/Novartis_painkiller_banned_after_deaths.html?cid=6050524 Novartis painkiller banned after deaths], Swissinfo.ch, August 2007</ref>
  
−
- Net income: 6 825
+
==Food safety issues==
  
−
Net income – Discontinued operations: 377
+
Syngenta inherits the dubious legacies of both parent companies, promoters of GMO (genetically modified organism) technology and manufacturers of hazardous chemicals (paraquat and atrazine11).  In the late 1990s Novartis and AstraZeneca wanted to establish themselves as "lifesciences" companies in order to exploit potential synergies between their pharmaceutical, chemical and agricultural sectors.  Both invested heavily in acquiring seed and biotechnology companies.  The Syngenta spin-off was a result of the poor performance of both companies' agribusiness divisions in 1999 and at least partially due to the global backlash against GM crops.
  
−
Net income – Total Group: 7 202
+
The creation of Syngenta enabled the parent companies to make considerable savings and rid themselves of their controversial agricultural biotechnology ventures.  Syngenta has so far managed to avoid the public vilification of [[Monsanto]], while it quietly develops controversial agricultural biotechnology, including genetic use restriction technologies (GURTs)/traitor technology. <ref>[http://www.corporatewatch.org.uk/?lid=212 Syngenta: A Corporate Profile], Corporate Watch, November 2002</ref> 
  
−
Basic earnings per share:
+
===Global GMOs & herbicide market===
 +
The top biotechnology companies are [[Monsanto]], [[DuPont]], [[Syngenta]] and [[Bayer]].  (Syngenta is a subsidiary of parent companies [[AstraZeneca]] and Novartis.  [[Aventis]]' agribusiness division was bought out by Bayer.)  They account for almost 100% of the genetically engineered seed and 60% of the global pesticide market.  Thanks to recent acquisitions, they now own 23% of the commercial seed market.  In 1999, almost 80% of total global transgenic acreage was planted in GMO soy, corn, cotton and canola.  Until then, farmers could spray herbicides before planting, but not after, as herbicides would kill the intended crop. The other 20% of genetically modified acreage is planted with crops that produce pesticides.  Monsanto’s "New Leaf" potato kills potato beetles, but is itself registered as a pesticide with the [[Environmental Protection Agency]] (EPA).  The five largest biotech companies in the world are also the five largest herbicide companies.  GMOs ensure a continuous and ever-expanding market for their agrochemicals. <ref>John Robbins [http://www.celsias.com/article/the-food-revolution-genetic-engineering-part-i/ Genetic Engineering, Part I], The Food Revolution, accessed December 2009</ref>
  
−
- Continuing operations1: 2.90
+
Under current policy, the government provides large subsidies to farmers to produce grains, in particularly corn and soybeans.  Livestock producers use corn and soy as a base for animal feed as they are protein rich and fatten up the animals.  They are also cheap (due to government subsidies.)  Livestock consumes 47% of the soy and 60% of the corn produced in the US. <ref>[http://www.sustainabletable.org/issues/feed/ The Issues: Corn and Soy], Sustainable Table, accessed December 2009</ref> See also [[FDA]].
  
−
- Total Group: 3.06
+
==Human rights & environmental abuses==
  
−
R&D investments1: 5 321
+
===Activists demand Syngenta leave Brazil===
 +
In December of 2007, hundreds of activists broke into Novartis' subsidiary Syngenta's agrochemical plant in Sao Paulo, Brazil.  According to a company spokesperson, 50 employees were expelled and production was shut down.  Members of the ''Landless Rural Workers’ Movement'' (MST) and its allied group ''Via Campesina'', destroyed genetically-modified corn and soy seedlings at a Syngenta farm in the northeastern state of Ceara.  The groups accused Syngenta of attacking landless workers and violating environmental laws and demanded that Syngenta leave Brazil.
  
−
- As % of net sales: 15.5
+
===Activist shot and killed protesting GMO fields===
 +
In October of 2007, an activist was shot and killed during a protest at a Syngenta farm in the southern Parana state.  According to the MST, the farm illegally produced genetically modified crops (GMO)'s within a protected enviromental zone close to the internationally acclaimed Iguacu water falls.  The Paraná State Federal Justice decided that experiments with GMOs in the surroundings of the Iguaçú National Park are illegal.  According to Judge Vanessa Hoffman, the park has a a 10 km buffer zone and the company was fined R$ 1 million by Brazilian environmental authorities.
  
−
Number of associates: 94 241
+
Syngenta is the world's largest agrochemical company.  According to a company statement, it was "dismayed by the occupations" but denied any participation in the October shooting death.  According to activists, the company's private security force at the farm were responsible for the shooting death of Valmir Mota de Oliveira.  The MST and other groups frequently occupy farms, block highways, torch crops and stage rallies to pressure the government to give land to the poor.  In response, landowners hire armed guards and hit squads to repel invasions.  Landless militants have also blocked railroads run by Brazilian mining companies, interupting the flow of iron ore to foreign markets.
  
−
For more information please view the 2007 Novartis Annual Financial report, found at: <ref>[http://www.novartis.com/investors/index.shtml "2007 Novartis Annual Financial report"]</ref>
+
Industry and agricultural [[lobbyist]]s have urged the government to crack down on landless movements, as they "undermine investment conditions in Brazil." <ref>Raymond Colitt, Vicki Allen [http://www.reuters.com/article/idUSN10291088 Brazil's landless peasants occupy Syngenta plants], [[Reuters]], December 2007</ref>  
  
−
==Business Strategy==
+
==Acquisitions, mergers, spin-offs & sell offs==
  
−
[[Image:2007-associates.jpg|thumb|NOVARTIS ASSOCIATES BY REGION AND BY BUSINESS]]
+
* Novartis was founded in 1996 in a merger of the Ciba-Geigy and Sandoz pharmaceutical companies. <ref>[http://www.novartis.com/about-novartis/company-history/index.shtml "Novartis History"], Novartis, accessed December 2008.</ref>
  
−
Novartis' business strategy can be outlined through its 6 major product-lines:
+
* After the merger, Novartis reorganized its activities.  The company spun out its chemicals activities as Ciba Specialty Chemicals, which became an independent company in January of 1997.<ref>[http://cibasc.com/index/cmp-index/cmp-about.htm "About Us"], Ciba, accessed December 2008</ref>
  
−
===Pharmaceuticals===
+
* Novartis combined its agricultural division with that of AstraZeneca to create Syngenta in November 2000, the first global group focusing exclusively on agribusiness. <ref>[http://www.syngenta.com/en/about_syngenta/companyhistory.html "Company History"], Syngenta, accessed December 2008.</ref>
  
−
The company's Pharmaceuticals portfolio includes more than 45 key marketed products, among which the following can be found<ref>[http://www.novartis.com/products/pharmaceuticals.shtml "Novartis Pharmaceuticals Division"]</ref>:
+
* In 2003, Novartis created a new company named Sandoz, a subsidiary that bundles its generic drug production by reusing the predecessor brand.<ref>[http://www.sandoz.it/site/it/l_azienda/News/Notizie/pool/Novartis_toSandoz.pdf "Return of a traditional name: Novartis Generics rebranded as Sandoz"], Sandoz Media Release, May 20, 2003</ref>
−
* Diovan HCT/Co-Diovan (valsartan and hydrochlorothiazide) for hypertension. (See [htttp://www.diovan.com here]
 
−
* Gleevec/Glivec (imatinib mesylate/imatinib); marketed to treat certain forms of leukemia, gastrointestinal stromal (GIST) tumors and various rare cancers; see [http://www.glivec.com here]
 
−
* Lamisil (terbinafine), an antifungal agent (see [http://www.lamisil.com here]
 
−
* Zometa (zoledronic acid) for cancers that have spread (or "metastasized") to the bones from solid tumors; see [http://www.zometa.com here]
 
  
−
===Vaccines and Diagnostics===
+
* In April of 2006, Novartis acquired the California based Chiron Corporation.  Chiron was formerly divided into three units: Chiron Vaccines and Chiron Blood Testing became Novartis Vaccines and Diagnostics.  Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. <ref>[http://www.allbusiness.com/company-activities-management/company-structures-ownership/5392342-1.html "Chiron Shareholders Approve Novartis Acquisition"], ''Media Release'', April 19 2006</ref>
−
Novartis' Vaccines and Diagnostics Division has specialized in the development of products to combat over 20 vaccine-preventable viral and bacterial diseases, as well as an array of sophisticated blood-testing equipment.
 
  
−
The current portfolio includes vaccines for:
+
* The company formerly owned Gerber baby products, which it sold to [[Nestlé]] in September of 2007. <ref>[http://www.novartis.com/newsroom/media-releases/en/2007/1150584.shtml "Novartis completes divestment program with transfer of Gerber baby foods business"], Novartis, Media Release, September 2007</ref>
  
−
* Influenza
+
* In September 2008 Ciba was bought by [[BASF]]. <ref>[http://www.corporate.basf.com/en/presse/mitteilungen/pm.htm?pmid=3229&id=V00-qN3bGDLaUbcp*WJ "BASF makes offer to acquire Ciba"], Media Release, September 15, 2008.</ref>, <ref>[http://www.iht.com/articles/2008/09/15/business/basf.php "BASF buys Swiss specialty chemicals maker Ciba"], ''International Herald Tribune'', September 15, 2008.</ref>
−
* Meningitis
 
−
* Rabies
 
−
* Tick-borne encephalitis
 
−
* Haemophilus influenzae type B (Hib)
 
−
* Polio
 
−
* Diphtheria
 
−
* Tetanus
 
−
* Pertussis (whooping cough)
 
  
−
Novartis is the world’s fifth-largest vaccines manufacturer and the second-largest supplier of influenza vaccines in the US.<ref>[http://www.novartis.com/products/vaccines.shtml "Novartis' Vaccines and Diagnostics Division"]</ref>
+
==Personnel & board==
  
−
===Sandoz===
+
===Board of directors===
 +
* [[Daniel Vasella]], M.D - Chairman & CEO
 +
* [[Ulrich Lehner]], PhD - Vice Chairman & Lead Director
 +
* [[Hans-Joerg Rudloff]] - Vice Chairman
 +
* [[Peter Burckhardt]], M.D.
 +
* [[Srikant Datar]], Ph.D.
 +
* [[William W. George]]
 +
* [[Alexandre F. Jetzer]]
 +
* [[Pierre Landolt]]
 +
* [[Andreas von Planta]], Ph.D.
 +
* [[Ing. Wendelin Wiedeking]]
 +
* [[Marjorie M. Yang]]
 +
* [[Rolf M. Zinkernagel]], M.D.
 +
* [[Ann Fudge]] <ref>[http://www.novartis.com/about-novartis/people/board-directors-committees.shtml People: Board of Directors], Novartis, accessed January 2010</ref>
  
−
Sandoz is the generic pharmaceuticals branch of Novartis, specializing in distributing and manufacturing a vast array of low-cost pharmaceutical products no longer protected by patents.  
+
===Executive committee===
 +
* [[Daniel Vasella]], M.D. - Chairman & CEO
 +
* [[Raymund Breu]], Ph.D. - Chief Financial Officer
 +
* [[Andreas Rummelt]], Ph.D. - Group Head, Quality Assurance & Technical Operations
 +
* [[Juergen Brokatzky-Geiger]], Ph.D. - Head, Human Resources
 +
* [[Mark C. Fishman]], MD - President, Novartis Institutes for Biomedical Research (NIBR)
 +
* [[Joseph Jimenez]] - CEO Pharmaceuticals
 +
* [[Joerg Reinhardt]], Ph.D. - COO, Novartis Group
 +
* [[Andreas Rummelt]], Ph.D. - Group Head of Quality Assurance & Technical Operations
 +
* [[Thomas Wellauer]], Ph.D. - Head, Corporate Affairs
 +
* [[Thomas Werlen]], Ph.D - General Counsel
  
−
"The key product groups of Sandoz include antibiotics, treatments for central-nervous-system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies."<ref>[http://www.novartis.com/products/sandoz.shtml "About Sandoz: Novartis' generic pharmaceuticals division"]</ref>
+
====Permanent attendees====
 +
* [[David Epstein]] - President & CEO, Oncology & Molecular Diagnostics
 +
* [[Jeffrey George]] - CEO, Sandoz
 +
* [[George Gunn]] - CEO, Consumer Health, President & CEO, Animal Health
 +
* [[Andrin Oswald]] - CEO Vaccines & Diagnostics
 +
* [[Jonathan Symonds]] - Deputy CFO & CFO designate, Novartis AG
  
−
===Over-the-counter drugs===
+
===Other Senior Management===
 +
* [[Paul Herrling]], Ph.D. - Head, Corporate Research
 +
* [[Bruno Heynen]] - Secretary to Executive Committee
 +
* [[Sheldon Jones]] - Head, Corporate Communications
 +
* [[Monika Matti]] - Corporate secretary
 +
* [[Leon V. Schumacher]] - Chief Information Officer <ref>[http://www.novartis.com/about-novartis/people/executive-committee.shtml People: Executive Committee], Novartis, accessed January 2010</ref>
  
−
"Over-the-Counter (OTC) is a world leader in the research, development, production and marketing of self-medication products that do not require prescriptions."<ref>[http://www.novartis.com/products/over-counter.shtml "Novartis' Over-the-counter product line"]</ref>
+
==Contact==
  
−
===Animal Health===
+
Novartis International AG <br>
−
 
+
Lichtstrasse 35<br>
−
"Animal Health focuses on the well-being of companion animals and on the health and productivity of farm animals. Our product range provides solutions for the prevention and treatment of several widespread animal diseases and parasite infestations."<ref>[http://www.novartis.com/products/animal-health.shtml "Novartis Animal Health"]</ref>
+
Basel<br>
−
 
+
CH-40-56<br>
−
===Ciba Vision===
+
Switzerland<br>
−
 
 
−
CIBA VISION specializes in contact lenses and lens-care production in over 70 countries<ref>[http://www.novartis.com/products/ciba-vision.shtml "CIBA Vision"]</ref>
 
−
 
 
−
==Corporate Accountability==
 
−
 
 
−
===Labor===
 
−
 
 
−
'''"Novartis - dealing with complexities of implementing a living wage"'''
 
−
 
 
−
"Based in Basel, this Swiss pharmaceutical company employs more than 101,000 people and operates in 140 countries. Its focus extends not only to the users of its products but to its employees as well being one of the first international companies to develop and implement a voluntary commitment to pay a living wage to all of its employees around the world. According to Novartis, to focus on a living rather than a minimum wage can contribute to stability and prosperity in communities and attract more skilled, productive and loyal employees. However, being one of the first companies to implement a living wage meant that it was done in the absence of universally accepted models. Novartis took a range of existing methodologies that considered specific geographic data and household expenditure for varying household sizes and places of residence."
 
−
 
 
−
===Human Rights===
 
−
 
 
−
'''"Misdeeds by pharmaceutical industry"'''
 
−
 
 
−
'''29-11-2006'''
 
−
 
 
−
"New medicines are often tested on people in developing countries in an unethical manner. The Wemos Foundation in Amsterdam, the Netherlands, finds it scandalous that the pharmaceutical industry exploits the weak position of people in developing countries. A new report from the Dutch Centre for Research on Multinational Corporations (SOMO) documents no fewer than 22 known cases in which the rights of trial subjects have been violated.
 
−
 
 
−
The report was released on Friday, 17 November during an event held to mark the silver jubilee of the Wemos Foundation. Liesbeth van der Kruit took such politicians as Diederik Samsom (PvdA) and Kees Vendrik(GroenLinks) to task about this issue during the Grote Verkiezingsshow (the Great Election Show). The report describes tests that involved various well-known pharmaceutical companies such as Novo Nordisk, Pfizer, Johnson & Johnson, Novartis, AstraZeneca and GlaxoSmithKline."<ref>[http://somo.nl/news-en/misdeeds-by-pharmaceutical-industry/?searchterm=novartis "Report from the Dutch Centre for Research on Multinational Corporations on unfair pharmaceutical trial practices"]</ref>
 
−
 
 
−
'''"Compulsory licensing “a last mechanism,” says Thai Health Minister"'''
 
−
 
 
−
'''August, 2008.''' "Thailand’s new Public Health Minister, Chawarat Charnveerakul, has said that imposing compulsory licensing (CL) is “the last mechanism” that the government would use “to help the poor get access to life-saving drugs at a fair price."
 
−
 
 
−
"First, we have to negotiate with drug firms to reduce the price of their drugs. If they do not agree with us we will then impose compulsory licensing for expensive drugs to save our patients’ lives," said Mr Chawarat, who was appointed to his post this month in a cabinet reshuffle. He added that his Ministry had not revoked the CL policy as a way of obtaining essential drugs, but retained it as “a key mechanism” in negotiating for lower prices."<ref>[http://pharmatimes.co.uk/Forums/forums/t/2065.aspx "Compulsory licensing on pharmaceutical drugs in Thailand"]</ref>
 
−
 
 
−
'''"Malaria campaigners hopeful on drugs pricing deal"'''
 
−
 
 
−
'''Septemeber, 2008.''' "Anti-malaria campaigners are confident that a deal can be reached with pharmaceuticals groups to cut the cost of new drugs needed to fight a disease estimated to kill more than 1 million people a year.
 
−
 
 
−
Negotiations are being held with several big drugs makers as part of a wider drive to bring the cost of so-called artemisinin-based combination therapies (ACTs) down to the level of the older, but now ineffective, chloroquinine treatments.
 
−
 
 
−
"I am very hopeful that this first stage, the negotiations, will produce results,"Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria told reporters in Paris on Tuesday."<ref>[http://www.alertnet.org/thenews/newsdesk/L9420228.htm "Malaria campaigners hopeful on drugs pricing deal"]</ref>
 
−
 
 
−
===Environment ===
 
−
 
 
−
'''USA: Novartis Phasing Out Genetically Engineered Foods'''
 
−
 
 
−
'''Environment News Service'''
 
−
 
 
−
'''August 4th, 2000'''
 
−
 
 
−
"Novartis, one of the world's leading producers of genetically engineered seeds, has been phasing out genetically engineered ingredients in its food products worldwide for over a year.
 
−
 
 
−
Responding to a statement issued by environmental group Greenpeace International yesterday, Novartis Consumer Health U.S. vice president Sheldon Jones told ENS there is nothing new about the company's stand on genetically engineered food.
 
−
 
 
−
Greenpeace cited a letter sent by Novartis' European Consumer Health department as evidence the company had stopped producing food containing genetically engineered ingredients in its own brands on June 30.
 
−
 
 
−
In particular, the letter stated production of the candy bar Cereal Chocosoja had been stopped because Novartis could not guarantee its non-GM quality."<ref>[http://www.corpwatch.org/article.php?id=681 "Novartis and Genetically Engineered Foods"]</ref>
 
−
 
 
−
===Consumer Protection and Product Safety===
 
−
 
 
−
'''"INDIA: Novartis Patents Case Far From Dead"'''
 
−
 
 
−
'''Inter Press Service News Agency'''
 
  
−
'''August 9th, 2007'''
+
Phone: +41-61-324-1111<br><ref>[http://www.hoovers.com/company/Novartis_AG/htscri-1.html Company Description: Novartis AG], Hoovers, accessed December 2009</ref>
  
−
"Cancer patients in India have reason to be relieved at a high court ruling this week which dismissed a petition by Swiss pharmaceuticals multinational corporation (MNC) Novartis challenging an Indian law which denies patents for minor or trivial improvements to known drugs. At immediate stake is the cost of a leukaemia drug, imatinib mesylate. Novartis prices its brand of the medicine, Gleevec/Glivec, at Rs 120,000 (3,000 US dollars) per dose. Indian generic drug manufacturers sell it at Rs 8,000 (200 dollars). India’s average per capita annual income is equivalent to only a fifth of the price of a single dose of Gleevec/Glivec. Had Novartis been granted a patent on its version of the drug, tens of thousands of Indians would have been deprived of life-saving treatment.<ref>[http://www.corpwatch.org/article.php?id=14631 "Novartis denied patent in India"]</ref>
+
Novartis Corporation <br>
 +
608 Fifth Ave. <br>
 +
New York, NY 10020 <br>
  
−
"The Berlin medical journal "arznei-telegramm" accused Novartis in 2002 of leaving out unfavourable results in the publication of a study of the drug Diovan, in order to make the efficacy of the drug look better than it actually was. The same journal also accused Novartis of illegal marketing practices and creating expectations of efficacy that could not be met."<ref>[http://www.consumersinternational.org "More Consumers International Claims on Novartis"]</ref>
+
Phone: 212-307-1122 <br><ref>[http://www.hoovers.com/company/Novartis_Corporation/rrcffyi-1.html Company Description: Novartis Corporation], Hoovers, accessed January 2010</ref>
  
−
"In 2002, the Swiss consumer protection agency Stiftung für Konsumentenschutz criticized Novartis for misleading consumers. Novartis had stated in its sales promotion that its drug Mebucasol F was new on the market, but the active ingredients would be the same as those of an older but cheaper drug with the name Sangerol."<ref>[http://www.consumersinternational.org "More Consumers International Claims on Novartis"]</ref>
+
Web address: http://www.novartis.com/  
  
−
===Anti-Trust and Tax Practices===
+
==Articles & sources==
−
 
 
−
'''Farmers Launch Anti-Trust Suit Against Monsanto'''
 
−
 
 
−
'''January 4th, 2000'''
 
−
 
 
−
"Six farmers -- from the U.S. and France -- named as representatives of farmers worldwide, under the aegis of the National Family Farm Coalition, in a suit formulated by Cohen Milstein Hausfeld & Toll on behalf of a consortium of other firms, have launched a major anti-trust, price fixing law suit against the Monsanto Corp. and nine corporate co-conspirators (including Novartis)"<ref>[http://www.corpwatch.org/article.php?id=574 "Farmers Launch Anti-Trust Suit Against Monsanto and Novartis"]</ref>
 
−
 
 
−
In 2004, a class action lawsuit was filed in the US against Novartis accused them of providing fraudulent kickbacks, discounts and rebates to encourage pharmacy benefits managers to put its drugs on their formularies. The case is still pending.<ref>[http://www.consumersinternational.org "Consumers International's list of claims against Novartis"]</ref>
 
−
 
 
−
===Social Responsibility Initiatives===
 
−
 
 
−
 
 
−
==Governance==
 
−
 
 
−
'''Board of Directors'''
 
−
* Daniel Vasella, M.D: Chairman and CEO
 
−
* Ulrich Lehner, Ph.D: Vice Chairman and Lead Director
 
−
* Hans-Joerg Rudloff: Vice Chairman
 
−
* Peter Burckhardt, M.D.
 
−
* Srikant Datar, Ph.D.
 
−
* William W. George
 
−
* Alexandre F. Jetzer
 
−
* Pierre Landolt
 
−
* Andreas von Planta, Ph.D.
 
−
* Dr. Ing. Wendelin Wiedeking
 
−
* Marjorie M. Yang
 
−
* Rolf M. Zinkernagel, M.D.
 
−
* Ann Fudge
 
−
 
 
−
'''Executive Comittee'''
 
−
* Daniel Vasella, M.D.: Chairman and CEO
 
−
* Andreas Rummelt, Ph.D.: Group Head of Quality Assurance and Technical Operations
 
−
* Joseph Jimenez: CEO Pharmaceuticals
 
−
* Joerg Reinhardt, Ph.D.: COO of the Novartis Group
 
−
* Juergen Brokatzky-Geiger, Ph.D: Head of Human Resources
 
−
* Mark C. Fishman, MD: President of the Novartis Institutes for Biomedical Research (NIBR)
 
−
* Raymund Breu, Ph.D.: Chief Financial Officer
 
−
* Thomas Wellauer, Ph.D.: Head of Corporate Affairs
 
−
* Thomas Werlen, Ph.D: General Counsel
 
−
 
 
−
'''Permanent Attendee of the Executive Committee'''
 
−
* Andrin Oswald: CEO Vaccines and Diagnostics
 
−
* David Epstein: President and CEO Oncology and Molecular Diagnostics
 
−
* George Gunn: CEO Consumer Health, President and CEO Animal Health
 
−
* Jeffrey George
 
−
 
 
−
==Contact Information==
 
−
Head Office
 
−
Novartis International AG <br>
 
−
CH-4002 Basel<br>
 
−
Switzerland<br>
 
−
Phone:  +41 61 324 11 11<br>
 
−
Fax: +41 61 324 80 01<br>
 
−
Website: http://www.novartis.com/ <br>
 
−
Monday - Friday, 8:30 - 17:00, GMT+1 (Central European Time)
 
  
−
==Articles and Resources==
+
===SourceWatch articles===
−
===Books on the Company===
+
* [[Agricultural Biotechnology Council]]
 +
* [[American Cancer Society]]
 +
* [[Animal testing]]
 +
* [[Argeris N. Karabelas]]
 +
* [[AstraZeneca]]
 +
* [[Biotechnology]]
 +
* [[Chemical companies, lobbyists and agribusiness]]
 +
* [[Covance Laboratories]]
 +
* [[Direct-to-consumer advertising in the United States]]
 +
* [[Food and Drug Administration]]
 +
* [[Environmentalism]]
 +
* [[Environmental activists who have been injured or killed]]
 +
* [[Humane Movement]]
 +
* [[Human rights]]
 +
* [[Huntingdon Life Sciences]]
 +
* [[National Primate Research Center System]]
 +
* [[Pharmaceutical industry]]
 +
* [[Prexige]]
 +
* [[SANE Australia]]
 +
* [[Syngenta]]
 +
* [[War on Cancer]]
  
−
===Related SourceWatch Articles===
+
===References===
 +
{{reflist|2}}
  
−
===Sources===
+
===External resources===
−
<references/>
+
* [http://www.gmwatch.org GM Watch], accessed January 2010
 +
* [http://novartiskills.com/Crimes.htm Novartis: A Chronicle of Crimes], Novartiskills.com, accessed January 2010
  
−
===External Resources===
 
−
* Consumers International: http://www.consumersinternational.org
 
−
* Business and Human Rights: http://www.business-humanrights.org
 
−
* Corporate Watch: http://www.corpwatch.org
 
−
* Centre for Research on Multinational Corporations: http://somo.nl/
 
  
−
===External Articles===
+
[[Category:ALEC Exposed]][[Category:Global corporations]][[Category:Pharmaceutical industry]][[Category:Animal testing]][[Category:Huntingdon Life Sciences]][[Category:Corporations]][[Category:Health]][[Category:Cancer]][[Category:Agriculture]][[Category:Gross Animal Welfare Violations]][[Category:Human rights abuses]][[Category:Biotechnology]]

Latest revision as of 19:57, 17 July 2017

Novartis
Type Private pharmaceutical company
Genre Pharmaceutical drug producer and biotechnological researcher
Founded 1996
Headquarters Basel, Switzerland

Novartis is a global pharmaceutical and biotechnology corporation with headquarters in Basel, Switzerland. The company specializes in biotechnological drugs, vaccines, over-the-counter pharmaceuticals, animal health care products, contact lenses and lense care products. It is the world's 5th largest vaccine producer. It distributes in over 140 countries through approximately 100,000 associates. [1] Novartis and AstraZeneca spun-off and merged to become Syngenta, a Swiss global agribusiness company formed in 2000 from the agrochemical and seed divisions of Novartis, and the agrochemicals and biotechnology research divisions of AstraZeneca. Syngenta is the world’s second biggest player in agrochemicals and the third biggest seed producer. [2]

In the fiscal year ending in December of 2009, the company reported sales of approximately $45.1 billion dollars and had 99,834 employees. [3]

Access Novartis's corporate rap sheet compiled and written by Good Jobs First here.

Overview

NOVARTIS ASSOCIATES BY REGION AND BUSINESS

Novartis' four divisions are pharmaceuticals, vaccines and diagnostics; generics and consumer health. Its largest division is pharmaceuticals. Vaccine and Diagnostics manufactures vaccines and blood-screening tools. Its Sandoz generics subsidiary produces generic drugs and active pharmaceutical ingredients. The consumer health unit includes the brand names Benefiber, Excedrin and Theraflu. It also includes contact lenses, eye care products, companion animal and agricultural animal products. See also Novartis products. [4]

Novartis has six major product lines: pharmaceuticals; vaccines & diagnostics; Sandoz generic drugs, Over-the Counter (OTC) self medication; animal products and CIBA vision contact lenses and lens-care products. The company markets over 50 key pharmaceutical products. In 2008 Novartis launched 11 products in the U.S. and the European Union (EU). [5] Novartis' Vaccines and Diagnostics Division in vaccine development and blood-testing equipment. The company is the fifth largest vaccine manufacturer in the world and the second largest supplier of influenza vaccines in he U.S. [6]

Sandoz is the generic branch of Novartis pharmaceuticals. It manufactures low cost pharmaceuticals no longer protected by patents. Key products include drugs for central-nervous-system, gastrointestinal and cardiovascular disorders as well as antibiotics and hormone therapies. [7] The company's over the counter (OTC) division develops, manufactures and markets non-prescription self medication. [8] Novartis manufactures products for companion animals and "the health and productivity of farm animals." Products include treatments for disease and parasite infestations. [9] CIBA VISION specializes in contact lenses and lens-care production in over 70 countries. [10]

Ties to the American Legislative Exchange Council

In August 2011, Novartis representative Don Stetcher was given the American Legislative Exchange Council's (ALEC's) 2011 Private Sector Member of the Year Award.[11]

About ALEC
ALEC is a corporate bill mill. It is not just a lobby or a front group; it is much more powerful than that. Through ALEC, corporations hand state legislators their wishlists to benefit their bottom line. Corporations fund almost all of ALEC's operations. They pay for a seat on ALEC task forces where corporate lobbyists and special interest reps vote with elected officials to approve “model” bills. Learn more at the Center for Media and Democracy's ALECexposed.org, and check out breaking news on our ExposedbyCMD.org site.

Animal testing

Demonstrations against Huntingdon Life Sciences clients Novartis & Merck. - Washington, DC January 2008

Novartis does animal testing.

Facility information, progress reports & USDA-APHIS reports

For links to copies of a facility's U.S. Department of Agriculture (USDA)-Animal Plant Health Inspection (APHIS) reports, other information and links, see also Stop Animal Experimentation NOW!: Facility Reports and Information. This site contains listings for all 50 states, links to biomedical research facilities in that state and PDF copies of government documents where facilities must report their animal usage. (Search: Cambridge, Massachusetts; San Diego, California.)

This facility performed animal experiments involving pain or distress but no analgesics, anesthetics or pain relievers were administered. For copies of this facility's USDA-APHIS reports, other information and links, see also Facility Reports and Information: Novartis Animal Vaccines, Inc., Larchwood, IA. [12]

This facility performed animal experiments involving pain or distress but no analgesics, anesthetics or pain relievers were administered. For copies of this facility's USDA-APHIS reports, other information and links, see also Facility Reports and Information: Novartis Pharmaceuticals Corporation, East Hanover, NJ[13]

USDA AWA reports

As of May 26, 2009, the USDA began posting all inspection reports for animal breeders, dealers, exhibitors, handlers, research facilities and animal carriers by state. See also USDA Animal Welfare Inspection Reports.

Contract testing

Novartis contract tests out to Huntingdon Life Sciences (HLS). [14] HLS is the 3rd largest contract research organization (CRO) in the world and the largest animal testing facility in all of Europe. Firms hire CROs to conduct animal toxicity tests for agrochemicals, petrochemicals, household products, pharmaceutical drugs and toxins. HLS has a long history of gross animal welfare violations. See also Huntingdon Life Sciences.

Novartis contract tests out to Covance Laboratories. [15] Covance has a long history of gross animal welfare violations. See also Covance Laboratories.

Animal cruelty & welfare violations

Violation Tracker
Discover Which Corporations are the Biggest Violators of Environmental, Health and Safety Laws in the United States
Violation Tracker is the first national search engine on corporate misconduct covering environmental, health, and safety cases initiated by 13 federal regulatory agencies. Violation Tracker is produced by the Corporate Research Project of Good Jobs First. Click here to access Violation Tracker.

Dairies of Despair: banned report released in UK

In April 2003, the largest ever set of data concerning animal experiments in the United Kingdom was released following a defeat earlier in the month for a 30 month injunction by Novartis and its former British subsidiary, Imutran. The documents revealed primates being used in the search for solutions to the chronic global shortage of human transplant organs. Baboons were transported from the African savannahs to die in steel cages the size of toilet cubicles. According to the documents, a quarter of the primates died from "technical failures". Researchers describe monkeys and baboons dying in fits of vomiting and diarrhea. Other symptoms were violent spasms, bloody discharges, grinding teeth and uncontrollable, manic eye movements. Animals retreated within themselves, lying still in their cages until they were put of their misery. Baboon W201m died of a stroke after two days of suffering from limb spasms and paralysis. Baboon W205m was "sacrificed" after 21 days. A genetically modified pig's heart had been attached to the vital arteries within its neck. Researchers noted the heart was swelling way beyond its natural size with a strange yellow fluid seeping from the organ.

Other animals never even made it to the Novartis contract laboratory, Huntingdon Life Sciences (HLS), suffering painful deaths en route. Faxes from global wildlife dealers reveal at least 50 baboons being taken from the African plains for the experiments. In one shipment, the creatures spent 34 hours in cramped transport crates; 10 hours longer than approved by the Home Office (which did not take any action.) In another shipment, three monkeys were found dead with blood oozing from their nostrils at a Paris airport. They had not been able to turn and lie down naturally. The 1,274 pages of documentation revealed a "litany of failings", including at least 520 errors and omissions. [16]

Xenotransplantation

The 150 page Diaries of Despair report based on the documentation, provides the public with an unprecedented and extensive insight into the reality of vivisection in Britain. Never before has so much secret information about animal experiments entered the public domain. The report was effectively banned for almost two and a half years by an injunction by Imutran and Novartis in late September of 2000. The leaked documentation reveals horrific animal suffering, corrects misleading public presentation of research and exposes government deception. The five part report provides background information on xenotransplantation (transplanting organs of one species into another); an overview of the leaked documents and the rationale behind transgenic pigs as a potential source of xenografts. It describe the suffering of primates used in the research and the legal framework regulating animal testing. The report documents baboons and cynomolgus monkeys, from (in the case of the baboons) capture in the wild, through transportation half way across the world and their deaths in experiments conducted at HLS.[17]

See also Dairies of Despair: Further Reading. [18]

Organ transplants are transplants are prohibitively expensive and of limited value. However, selling transgenic pig parts and other organs is very profitable. Novartis and its subsidiaries have killed thousands of animals and spent millions of dollars attempting to develop animal organs for transplantation into humans. Xenotransplantation experiments have a long history of human and animal costs. They have proved to be one of the greatest medical disasters of all time, for both animals and recipients. Approximately 6,000 people are on waiting lists for human organs, an organ shortage which could largely be solved through default consent to organ donation after death. See also Humane Movement, section 5.

Imunopigs

In spite of 100 years of failed research, the quest to turn animals into spare parts warehouses continues and has done nothing to slow Novartis' search for an immunopig; (pigs genetically manipulated to carry human genes.) However, failed research has shown that animals transplanted with human genes do not have suitable spare parts for humans, any more than non-genetically altered animals do. Other species such as hamsters, rabbits and monkeys have also been subjected to failed horrific and pointless xenotransplantation. The surgeries are so monumentally unsuccessful that animals usually begin to die within minutes.

Organ failure, rejection & dangers to human health

The transplanted organs do not function or are rejected almost instantaneously. In one experiment, a pig's kidney was accidentally transplanted into the abdomen of a monkey. The victims are then overdosed with anesthetics and their spleens were removed. Monkeys and baboons who survive xenotransplanation die of organ rejection, organ failure and infections from drug toxicity and impaired immune systems. Novartis has subjected monkeys to lethal infections, lethal blood clotting, bleeding complications, viral and protozoal infections, lymph cancer, severe nausea, severe stomach inflammation and diarrhea, dehydration, fatal pneumonia, persistent wound infections, breakdowns, brain trauma, heart attacks, pneumonia and anemia. Primates are also given massive doses of immune-suppressing drugs which cause internal hemorrhaging. In one experiment, a swab was left in a monkey's abdomen which in turn caused a lethal infection. Such incidents occur on a regular basis.

Some animal viruses are impossible to eradicate and can infect humans. Current and historic examples mad cow disease, HIV, avian flu and the 1918 influenza epidemic. Scientists have expressed concern that recipients of pig organs may pass viruses into the general population. [19], [20]

Induced schizophrenia & epilepsy in rats & mice

In experiments in Basel, Switzerland, rats Rats between 4 and 8 days age are deprived of oxygen. Some are exposed to reduced oxygen content. Some of them are killed on the 11th day of oxygen deprivation and their brains cut out and examined. Others are exposed to noise and rattled in steel cages until they begin to show symptoms of schizophrenia. Finally, on their 120th day the rats are killed.

In experiments in Germany on rats supplied by the Basel laboratory, electrodes are implanted into the stomachs and brains of mice. Pilokarpin (a drug used to treat dry mouth associated with cancer radiotion treatment) is then injected to induce epilepsy. Some of the mice die due to the treatment and others are again killed and their brains examined. Surviving mice and subjected to a second injection of the drug Diazepam (Valium). They live up to 28 days with the implanted electrodes before they are killed. [21]

Drilling open the heads of cats

In Germany experiments, the heads of cats are drilled open and a glass plate is applied. Pictures are shown to the cat and the brain is filmed through the glass plate. The cats are killed after 30 to 45 minutes. Martin Rausch of Novartis Pharma AG, Basel, Switzerland, participated in these experiments. [22], [23]

Drug safety issues

Novartis has been plagued by a number of recent drug safety issues, including the delay of its diabetes drug Galvus and "evaluating" the launch of a generic version of its Lotrel blood pressure treatment. Novartis withdrew the bowel drug Zelnorm from US shelves in March of 2007.

Prexige banned in Australia

In August of 2007, Australia banned Novartis' Prexige, after the deaths of two patients. According to Australia's Therapeutic Goods Administration (TGA), it received 8 reports of serious liver damage, including two deaths and two liver transplants linked to the COX-2 painkiller.

In spite of these developments, there were no plans to pull the drug elsewhere, according to a company spokes person. The company also planned to proceed with filing for marketing approval in the United States. COX-2s have been under a cloud since Merck withdrew Vioxx in 2004 after studies showed that it increased the risk for heart attacks. There have also been concerns over other non-steroidal, anti-inflammatory drugs. Prexige had been viewed as a blockbuster seller for Novartis until the Vioxx withdrawal. [24]

Food safety issues

Syngenta inherits the dubious legacies of both parent companies, promoters of GMO (genetically modified organism) technology and manufacturers of hazardous chemicals (paraquat and atrazine11). In the late 1990s Novartis and AstraZeneca wanted to establish themselves as "lifesciences" companies in order to exploit potential synergies between their pharmaceutical, chemical and agricultural sectors. Both invested heavily in acquiring seed and biotechnology companies. The Syngenta spin-off was a result of the poor performance of both companies' agribusiness divisions in 1999 and at least partially due to the global backlash against GM crops.

The creation of Syngenta enabled the parent companies to make considerable savings and rid themselves of their controversial agricultural biotechnology ventures. Syngenta has so far managed to avoid the public vilification of Monsanto, while it quietly develops controversial agricultural biotechnology, including genetic use restriction technologies (GURTs)/traitor technology. [25]

Global GMOs & herbicide market

The top biotechnology companies are Monsanto, DuPont, Syngenta and Bayer. (Syngenta is a subsidiary of parent companies AstraZeneca and Novartis. Aventis' agribusiness division was bought out by Bayer.) They account for almost 100% of the genetically engineered seed and 60% of the global pesticide market. Thanks to recent acquisitions, they now own 23% of the commercial seed market. In 1999, almost 80% of total global transgenic acreage was planted in GMO soy, corn, cotton and canola. Until then, farmers could spray herbicides before planting, but not after, as herbicides would kill the intended crop. The other 20% of genetically modified acreage is planted with crops that produce pesticides. Monsanto’s "New Leaf" potato kills potato beetles, but is itself registered as a pesticide with the Environmental Protection Agency (EPA). The five largest biotech companies in the world are also the five largest herbicide companies. GMOs ensure a continuous and ever-expanding market for their agrochemicals. [26]

Under current policy, the government provides large subsidies to farmers to produce grains, in particularly corn and soybeans. Livestock producers use corn and soy as a base for animal feed as they are protein rich and fatten up the animals. They are also cheap (due to government subsidies.) Livestock consumes 47% of the soy and 60% of the corn produced in the US. [27] See also FDA.

Human rights & environmental abuses

Activists demand Syngenta leave Brazil

In December of 2007, hundreds of activists broke into Novartis' subsidiary Syngenta's agrochemical plant in Sao Paulo, Brazil. According to a company spokesperson, 50 employees were expelled and production was shut down. Members of the Landless Rural Workers’ Movement (MST) and its allied group Via Campesina, destroyed genetically-modified corn and soy seedlings at a Syngenta farm in the northeastern state of Ceara. The groups accused Syngenta of attacking landless workers and violating environmental laws and demanded that Syngenta leave Brazil.

Activist shot and killed protesting GMO fields

In October of 2007, an activist was shot and killed during a protest at a Syngenta farm in the southern Parana state. According to the MST, the farm illegally produced genetically modified crops (GMO)'s within a protected enviromental zone close to the internationally acclaimed Iguacu water falls. The Paraná State Federal Justice decided that experiments with GMOs in the surroundings of the Iguaçú National Park are illegal. According to Judge Vanessa Hoffman, the park has a a 10 km buffer zone and the company was fined R$ 1 million by Brazilian environmental authorities.

Syngenta is the world's largest agrochemical company. According to a company statement, it was "dismayed by the occupations" but denied any participation in the October shooting death. According to activists, the company's private security force at the farm were responsible for the shooting death of Valmir Mota de Oliveira. The MST and other groups frequently occupy farms, block highways, torch crops and stage rallies to pressure the government to give land to the poor. In response, landowners hire armed guards and hit squads to repel invasions. Landless militants have also blocked railroads run by Brazilian mining companies, interupting the flow of iron ore to foreign markets.

Industry and agricultural lobbyists have urged the government to crack down on landless movements, as they "undermine investment conditions in Brazil." [28]

Acquisitions, mergers, spin-offs & sell offs

  • Novartis was founded in 1996 in a merger of the Ciba-Geigy and Sandoz pharmaceutical companies. [29]
  • After the merger, Novartis reorganized its activities. The company spun out its chemicals activities as Ciba Specialty Chemicals, which became an independent company in January of 1997.[30]
  • Novartis combined its agricultural division with that of AstraZeneca to create Syngenta in November 2000, the first global group focusing exclusively on agribusiness. [31]
  • In 2003, Novartis created a new company named Sandoz, a subsidiary that bundles its generic drug production by reusing the predecessor brand.[32]
  • In April of 2006, Novartis acquired the California based Chiron Corporation. Chiron was formerly divided into three units: Chiron Vaccines and Chiron Blood Testing became Novartis Vaccines and Diagnostics. Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. [33]
  • The company formerly owned Gerber baby products, which it sold to Nestlé in September of 2007. [34]

Personnel & board

Board of directors

Executive committee

Permanent attendees

Other Senior Management

Contact

Novartis International AG
Lichtstrasse 35
Basel
CH-40-56
Switzerland

Phone: +41-61-324-1111
[39]

Novartis Corporation
608 Fifth Ave.
New York, NY 10020

Phone: 212-307-1122
[40]

Web address: http://www.novartis.com/

Articles & sources

SourceWatch articles

References

  1. ↑ Welcome to Novartis, Novartis, January 2010
  2. ↑ Syngenta: A Corporate Profile, Corporate Watch, November 2002
  3. ↑ Key Novartis AG Financials, Hoovers, accessed January 2011
  4. ↑ Welcome to Novartis, Novartis, accessed December 2009
  5. ↑ Welcome to Novartis: Pharmaceuticals, accessed December 2009
  6. ↑ Novartis Vaccines and Diagnostics Division", Novartis, accessed December 2008
  7. ↑ About Sandoz: Novartis' generic pharmaceuticals division, Norvartis, accessed January 2009
  8. ↑ "Novartis' Over-the-counter product line", Novartis, accessed January 2009
  9. ↑ Novartis Animal Health, Novartis, accessed January 2009
  10. ↑ CIBA Vision, Novartis, accessed January 2009
  11. ↑ American Legislative Exchange Council, "Solutions for the States," 38th Annual Meeting agenda, on file with CMD, August 3-6, 2011
  12. ↑ Facility Reports and Information: Novartis Animal Vaccines, Inc., Larchwood, IA,Stop Animal Experimentation NOW!, accessed January 2011
  13. ↑ Facility Reports and Information: Novartis Pharmaceuticals Corporation, East Hanover, NJ, SAEN, accessed January 2011
  14. ↑ Inside Customers, SHAC.net, accessed December 2009
  15. ↑ Novartis - A Chronicle of Crimes, Novartiskills.com, acessed January 2010
  16. ↑ Mark Townsend Exposed: secrets of the animal organ lab, The Observer, April 2003
  17. ↑ Dairies of Despair: The Secret History of pig-to-primate organ transplants, Uncaged Campaigns, accessed January 2010
  18. ↑ Dairies of Despair: Further Reading, Uncaged Campaigns, accessed January 2010
  19. ↑ PETA Names the 10 Worst CEOs for Animals in Laboratories, People for the Ethical Treatment of Animals, accessed December 2009
  20. ↑ Xenografts: Frankenstein Science, PETA Media Center, accessed January 2010
  21. ↑ Journal of Neural Transmission 2007: 114, 239-248
  22. ↑ Neuro Report 2001: 12, 1693-1698
  23. ↑ Novartis: A Chronicle of Crimes: Animal Torture, Novartiskills.com, accessed January 2010
  24. ↑ Novartis painkiller banned after deaths, Swissinfo.ch, August 2007
  25. ↑ Syngenta: A Corporate Profile, Corporate Watch, November 2002
  26. ↑ John Robbins Genetic Engineering, Part I, The Food Revolution, accessed December 2009
  27. ↑ The Issues: Corn and Soy, Sustainable Table, accessed December 2009
  28. ↑ Raymond Colitt, Vicki Allen Brazil's landless peasants occupy Syngenta plants, Reuters, December 2007
  29. ↑ "Novartis History", Novartis, accessed December 2008.
  30. ↑ "About Us", Ciba, accessed December 2008
  31. ↑ "Company History", Syngenta, accessed December 2008.
  32. ↑ "Return of a traditional name: Novartis Generics rebranded as Sandoz", Sandoz Media Release, May 20, 2003
  33. ↑ "Chiron Shareholders Approve Novartis Acquisition", Media Release, April 19 2006
  34. ↑ "Novartis completes divestment program with transfer of Gerber baby foods business", Novartis, Media Release, September 2007
  35. ↑ "BASF makes offer to acquire Ciba", Media Release, September 15, 2008.
  36. ↑ "BASF buys Swiss specialty chemicals maker Ciba", International Herald Tribune, September 15, 2008.
  37. ↑ People: Board of Directors, Novartis, accessed January 2010
  38. ↑ People: Executive Committee, Novartis, accessed January 2010
  39. ↑ Company Description: Novartis AG, Hoovers, accessed December 2009
  40. ↑ Company Description: Novartis Corporation, Hoovers, accessed January 2010

External resources

Retrieved from "https://www.sourcewatch.org/index.php?title=Novartis&oldid=713043"